Despite its infrequent occurrence, it is still associated with therapy-related myelodysplastic syndrome (MDS)/AML, relapsed AML, and poor survival compared to TP53 wild-type AML [63,78]. The gene discussed is TP53; the disease is acute myeloid leukemia.